22:14 , Mar 1, 2019 |  BioCentury  |  Product Development

Prostate cancer disrupted

Two imminent disruptions threaten to upend the treatment landscape for prostate cancer, changing who gets anti-androgen therapies and ushering in the first new MOAs in decades. The launch of generic abiraterone means next generation anti-androgens...
19:28 , Sep 10, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Patient-derived oligocortical spheroids could be used to study demyelinating diseases and screen therapies to treat them. The spheroids were generated by culturing human pluripotent stem cells with platelet derived growth factor AA...
01:46 , Aug 17, 2018 |  BC Innovations  |  Targets & Mechanisms

Unsaturated remyelination

Enzymes downstream in cholesterol biosynthesis could provide new ways to stimulate remyelination that avoid the baggage of previously identified multiple sclerosis targets, according to a group at Case Western. The university is spinning out Convelo...
18:29 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

Strongbridge's Cushing syndrome candidate meets in Phase III

Strongbridge Biopharma plc (NASDAQ:SBBP) said Recorlev levoketoconazole met the primary and secondary endpoints in the Phase III SONICS trial to treat endogenous Cushing syndrome. On the 94-patient trial's primary endpoint, 30% of patients achieved normalization...
21:13 , Apr 17, 2018 |  BC Innovations  |  Distillery Techniques

Disease models; drug properties

TECHNOLOGY: 3-D models; pharmacokinetics/pharmacodynamics 3-D human intestinal organoids could be used to test the PK properties of drug compounds. The organoids are generated by culturing human induced pluripotent stem (iPS) cells in a medium containing...
16:54 , Oct 6, 2017 |  BC Week In Review  |  Financial News

NewLink, Strongbridge price follow-ons

NewLink Genetics Corp. (NASDAQ:NLNK) and Strongbridge Biopharma plc (NASDAQ:SBBP) each priced follow-ons, raising more than $75 million. On Oct. 3, NewLink raised $51.3 million through the sale of 5 million shares at $10.25 in a...
21:14 , Oct 4, 2017 |  BC Extra  |  Financial News

NewLink, Strongbridge price follow-ons

NewLink Genetics Corp. (NASDAQ:NLNK) and Strongbridge Biopharma plc (NASDAQ:SBBP) each priced follow-ons, raising more than $75 million. NewLink raised $51.3 million through the sale of 5 million shares at $10.25 in a bumped-up follow-on underwritten...
19:59 , Apr 11, 2017 |  BC Innovations  |  Distillery Techniques

Drug properties; other

TECHNOLOGY: Pharmacokinetics / pharmacodynamics; drug-drug interactions; computational models A computational model for predicting the PK of ATRA could aid the design of ATRA-dosing strategies and identify drug-drug interactions that could help overcome resistance caused by...
07:00 , Mar 24, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Drug-responsive transcription factor PDR1 (PDR1); mediator complex subunit 15 (MED15)

Infectious disease INDICATION: Fungal infection Cell culture, moth and mouse studies suggest inhibiting the microbial PDR1- MED15 interaction could help treat multidrug-resistant (MDR) fungal infections, which frequently involve gain-of-function mutations in PDR1 . Screening of...
01:30 , Oct 17, 2015 |  BC Extra  |  Financial News

Strongbridge raises $25M in U.S. listing

Strongbridge Biopharma plc (NASDAQ:SBBP) gained $0.05 to $10.05 in its first day of trading on NASDAQ on Friday after it raised $25 million through the sale of 2.5 million shares at $10 in a deal...